Abstract
To date, the most immunotherapy drugs act upon T cell surface proteins to promote tumoricidal T cell activity. However, this approach has to date been unsuccessful in certain solid tumor types including pancreatic, prostate cancer and glioblastoma. Myeloid-related innate immunity can promote tumor progression through direct and indirect effects on T cell activity; improved understanding of this field may provide another therapeutic avenue for patients with these tumors. Myeloid cells can differentiate into both pro-inflammatory and anti-inflammatory mature form depending upon the microenvironment. Most cancer type exhibit oncogenic activating point mutations (ex. P53 and KRAS) that trigger cytokines production. In addition, tumor environment (ex. Collagen, Hypoxia, and adenosine) also regulated inflammatory signaling cascade. Both the intrinsic and extrinsic factor driving the tumor immune microenvironment and regulating the differentiation and function of myeloid cells, T cells activity and tumor progression. In this review, we will discuss the relationship between cancer cells and myeloid cells-mediated tumor immune microenvironment to promote cancer progression and immunotherapeutic resistance. Furthermore, we will describe how cytokines and chemokines produced by cancer cells influence myeloid cells within immunosuppressive environment. Finally, we will comment on the development of immunotherapeutic strategies with respect to myeloid-related innate immunity.
Highlights
Inflammation and Myeloid Cells in Cancer Progression and MetastasisReviewed by: Rachna Shah, Memorial Sloan Kettering Cancer Center, United States Rajni Kant Shukla, The Ohio State University, United States Rajni Kumari, Albert Einstein College of Medicine, United States
With solid tumors, the TME is complex and contains cancer, immune and stromal cells within a confined, three-dimensional space
A recent study suggests that Myeloid-derived suppressor cells (MDSCs)-mediated TGF-β and IL-10 play an important role in developmental of CD4+ CD25+ Treg cells, which can significantly suppress antigen-specific immune responses. (Huang et al, 2006)
Summary
Reviewed by: Rachna Shah, Memorial Sloan Kettering Cancer Center, United States Rajni Kant Shukla, The Ohio State University, United States Rajni Kumari, Albert Einstein College of Medicine, United States. The most immunotherapy drugs act upon T cell surface proteins to promote tumoricidal T cell activity. This approach has to date been unsuccessful in certain solid tumor types including pancreatic, prostate cancer and glioblastoma. Myeloid-related innate immunity can promote tumor progression through direct and indirect effects on T cell activity; improved understanding of this field may provide another therapeutic avenue for patients with these tumors. Hypoxia, and adenosine) regulated inflammatory signaling cascade Both the intrinsic and extrinsic factor driving the tumor immune microenvironment and regulating the differentiation and function of myeloid cells, T cells activity and tumor progression. We will discuss the relationship between cancer cells and myeloid cellsmediated tumor immune microenvironment to promote cancer progression and immunotherapeutic resistance. We will comment on the development of immunotherapeutic strategies with respect to myeloid-related innate immunity
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.